Glaxo's China scandal ate into CEO's bonus; Martoma wants a new trial after insider trading conviction;

@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech

@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce

@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce

@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce

> GlaxoSmithKline's ($GSK) China bribery scandal cost CEO Andrew Witty up to $410,000 in potential bonus money. Story

> Mathew Martoma, the ex-SAC fund manager convicted of insider trading, is asking a judge to toss that verdict and grant him a new trial, arguing that prosecutors failed to prove he obtained secret information before selling off shares of Wyeth and Elan. Article

> Perrigo is handing over ELND005, a former Elan treatment for Alzheimer's disease, to Transition Therapeutics ($TTHI) for an undisclosed sum, also making a $15 million investment in the biotech. More

Medical Device News

@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev

@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce

@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce

> HeartWare's heart pump revenue jumped in Q4, thanks to U.S. growth. News

> Illumina's prenatal blood test shows standout results in NEJM. More

> S. Korea is trying to decide whether the Galaxy S5 is a medical device. Story

Pharma News

@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma

@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton

@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce

@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce

> GSK trims Witty's bonus in face of China probe. Story

> Endo loss widens, R&D chief departs amid regulatory struggles. Article